gastrointestinal cancer
Conditions
Interventions
Experimental group:propranolol
Control:Placebo
Sponsors
Department of Clinical Pharmacology, XiangYa Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) patients with gastric adenocarcinoma and colon cancer were diagnosed by histology and cytology, and there was a clear metastasis (TxNxM0); (2) without any prior treatment (including surgery or radiotherapy and chemotherapy) in the I-III period, no distant metastasis, suitable for patients with surgical resection of the tumor; (3) Aged 18-60 years; (4) systolic pressure 100-140mmHg; heart rate >60bpm; (5) the patient's survival time should be longer than 3 months; (6) without previous cardiovascular and cerebrovascular diseases, the atrioventricular block was excluded by the 24 hour dynamic electrocardiogram; (7) ECOG score of 2 (that means the patient's bed time is less than 50%); Karnofsky score of 60% (that means patients have the basic activities and self-care ability); (8) the basic biochemical examination results of patients with normal: white blood cell 3000/ul; neutrophil 1500/ul 100000/ul; platelet count; total bilirubin < 1.5 x ULN; AST / ALT 2.5 x ULN without liver metastasis; < 5 x ULN liver metastasis; creatinine clearance rate of 1.5 x ULN; (9) have the ability to understand and sign informed consent.
Exclusion criteria
Exclusion criteria: (1) pregnant or lactating women; (2) patients with severe heart disease, kidney disease, metabolic disorders, bronchial asthma, cardiogenic shock, heart block (II-III degree atrioventricular block), or severe acute heart failure, sinus bradycardia. (3) patients with epilepsy or psychotropic drugs and sedatives; (4) patients with brain metastasis and bone marrow metastasis; (5) participants in clinical trials of other drugs within 4 weeks; (6) patients with a history of anaphylaxis with propranolol; (7) patients treated with trastuzumab; (8) patients with or reactive immunodeficiency, such as those with HIV infection; (9) the uncontrollable situation in the group during the period (but not limited to these cases): according to the experimental scheme of medication, severe infection, due to mental illness or other social factors lead to the compliance requirements of patients; (10) patients with atrioventricular block should be discontinued immediately and quit; (11) the researchers believe there may be any increase in the risk of the subject or any interference with clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tumor size; | — |
Countries
China
Contacts
Public ContactHe Yijing
Department of Clinical Pharmacology, Xiangya Hospital, Central South University
Outcome results
None listed